Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The objective of this case-control study was to compare the efficacy and toxicity of lenalidomide plus dexamethasone (len/dex) versus thalidomide plus dexamethasone (thal/dex) as initial therapy for newly diagnosed myeloma. We retrospectively studied 411 newly diagnosed patients treated with len/dex (228) or thal/dex (183) at the Mayo Clinic. The differences were similar in a matched-pair analysis that adjusted for age, sex, transplantation status, and dexamethasone dose. The proportions of patients achieving at least a partial response to len/dex and thal/dex were 80.3% versus 61.2%, respectively (P < .001); very good partial response rates were 34.2% and 12.0%, respectively (P < .001). Patients receiving len/dex had longer time to progression (median, 27.4 vs 17.2 months; P = .019), progression-free survival (median, 26.7 vs 17.1 months; P = .036), and overall survival (median not reached vs 57.2 months; P = .018). A similar proportion of patients in the 2 groups experienced at least one grade 3 or 4 adverse event (57.5% vs 54.6%, P = .568). Main grade 3 or 4 toxicities of len/dex were hematologic, mainly neutropenia (14.6% vs 0.6%, P < .001); the most common toxicities in thal/dex were venous thromboembolism (15.3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · cited 1×
“Lenalidomide (CC-5013), an analogue of thalidomide, is more potent in preclinical assays than thalidomide(9,10) and has fewer non-hematologic side-effects compared to the parent drug.(11,12) In newly diagnosed patients, lenalidomide plus high-dose dexamethasone was”
BackgroundLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233 · cited 1×
“Lenalidomide (CC-5013), an analogue of thalidomide, is more potent in preclinical assays than thalidomide(9,10) and has fewer non-hematologic side-effects compared to the parent drug.(11,12) In newly diagnosed patients, lenalidomide plus high-dose dexamethasone was”
BackgroundSelf-citationRajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865 · cited 2×
“001) as were DVT (17% vs 3%) and grade 3-4 peripheral neuropathy (7% vs 4%).(5) A prospective randomized study confirmed the efficacy of thal/dex regimen also in comparison with the standard VAD regimen.”
BackgroundSelf-citationRichardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Self-citation
Cited by
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 741
IMWG consensus on risk stratification in multiple myeloma
Chng, W. J., Dispenzieri, A., Chim, C.-S., Fonseca, R., Goldschmidt, H., Lentzsch, S., Munshi, N., Palumbo, A., Miguel, J. S., Sonneveld, P., et al. (2014) · Leukemia · doi:10.1038/leu.2013.247 · Cited by 601
Self-citationMateos, M.-V., Oriol, A., Martínez-López, J., Gutiérrez, N., Teruel, A.-I., de Paz, R., García-Laraña, J., Bengoechea, E., Martín, A., Mediavilla, J. D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70187-x · Cited by 458
Rajkumar, S. V. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.63 · Cited by 289
Self-citationManagement of treatment-emergent peripheral neuropathy in multiple myeloma
Richardson, P. G., Delforge, M., Beksac, M., Wen, P., Jongen, J. L., Sezer, O., Terpos, E., Munshi, N., Palumbo, A., Rajkumar, S. V., et al. (2012) · Leukemia · doi:10.1038/leu.2011.346 · Cited by 253
Self-citation
Metadata
- Authors
- Gay, F., Hayman, S. R., Lacy, M. Q., Buadi, F., Gertz, M. A., Kumar, S., Dispenzieri, A., Mikhael, J. R., Bergsagel, P. L., Dingli, D., Reeder, C. B., Lust, J. A., Russell, S. J., Roy, V., Zeldenrust, S. R., Witzig, T. E., Fonseca, R., Kyle, R. A., Greipp, P. R., Stewart, A. K., & Rajkumar, S. V.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2010-02-18
- Volume
- 115
- Issue
- 7
- Pages
- 1343-1350
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2064601405
- Cited by
- 124
- References
- 5
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. https://app.cochat.ai/papers/10.1182/blood-2009-08-239046
- The paper
- Gay, F., Hayman, S. R., Lacy, M. Q., Buadi, F., Gertz, M. A., Kumar, S., Dispenzieri, A., Mikhael, J. R., Bergsagel, P. L., Dingli, D., Reeder, C. B., Lust, J. A., Russell, S. J., Roy, V., Zeldenrust, S. R., Witzig, T. E., Fonseca, R., Kyle, R. A., Greipp, P. R., . . . Rajkumar, S. V. (2010). Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. https://doi.org/10.1182/blood-2009-08-239046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.